Is Semaglutide Safe During Pregnancy?

Semaglutide, known under brand names like Ozempic, Wegovy, and Rybelsus, has become a widely used treatment for type 2 diabetes and obesity. With increasing popularity among women of reproductive age, questions about its safety during pregnancy are becoming more urgent. This article explores the available evidence, clinical guidelines, and key considerations for women who are pregnant, trying to conceive (TTC), or may become pregnant while using semaglutide.

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist, a class of drugs that mimics a hormone involved in glucose regulation and appetite control. Initially approved for type 2 diabetes, it has also been approved for chronic weight management due to its significant effect on reducing body weight. It is administered either as a weekly injection (Ozempic and Wegovy) or a daily oral tablet (Rybelsus).

These medications slow down gastric emptying, promote insulin secretion, and reduce appetite—factors that help regulate blood sugar and support weight loss. However, their use during pregnancy is controversial due to insufficient safety data.

Why Women of Reproductive Age Take Semaglutide

Semaglutide is increasingly used not just by people with diabetes, but by those with obesity, insulin resistance, PCOS, and prediabetes—conditions that affect many women of childbearing age. Weight management before pregnancy is often recommended to reduce risks of gestational diabetes, hypertension, and other complications. Some women also start semaglutide as part of a pre-conception health plan to improve their overall metabolic health.

Given this expanded use, it’s critical to understand how semaglutide may impact early pregnancy—especially if conception occurs unintentionally during treatment.

GLP-1 Medications and Pregnancy: Known Risks

Currently, no well-controlled human studies assess the safety of semaglutide in pregnant women. Available data primarily comes from animal studies, which have raised concerns:

• In rats and rabbits, semaglutide exposure during organogenesis led to fetal abnormalities, growth restriction, and early pregnancy loss, especially at higher doses.
  
• The mechanism may be related to inadequate fetal nutrient delivery or interference with implantation and early embryonic development.
  

Because of this, the FDA categorizes semaglutide as pregnancy risk Category C, which means animal studies have shown adverse effects, and there are no adequate human studies to rule out risk.

Guidelines for Semaglutide in Pregnancy

The current clinical recommendation is clear:

Semaglutide should be discontinued prior to pregnancy.

Specific guidance includes:

• FDA Labeling: Semaglutide is not recommended during pregnancy due to unknown safety.
  
• American Diabetes Association (ADA) and Endocrine Society recommend stopping all GLP-1 receptor agonists when planning pregnancy or once pregnancy is confirmed.
  

For women with type 2 diabetes, insulin or metformin are preferred during pregnancy, as they have a long-standing safety profile.

Similarly, for those using semaglutide for weight loss, the use of the drug is considered inappropriate once pregnancy is being pursued or confirmed.

What If You Become Pregnant on Semaglutide?

Accidental pregnancies do happen, particularly given that semaglutide can affect menstrual regularity and fertility by reducing insulin resistance. In such cases, here’s what is typically advised:

• Stop semaglutide immediately once pregnancy is confirmed.
  
• Notify your healthcare provider to review prenatal care and monitor early development closely.
  
• Most reported exposures in early pregnancy have not resulted in documented birth defects, but the data is limited and anecdotal.
  

A 2023 post-marketing surveillance analysis noted a small number of unintentional first-trimester exposures to semaglutide, but no consistent pattern of birth defects has been observed—however, the numbers are too low to draw conclusions.

Discontinuing Semaglutide Before Conception

Due to the long half-life of semaglutide (up to 7 days), it can remain in the body for 5–6 weeks after the last dose. That’s why most guidelines recommend:

• Stopping semaglutide at least 2 months before trying to conceive.
  
• This washout period allows the drug to fully clear from the system before ovulation and implantation occur.
  

If a woman is considering IVF or other fertility treatments, some clinics may delay procedures until semaglutide has been fully eliminated from the body.

Current Gaps in Research

Despite widespread use, major gaps remain:

• No randomized controlled trials (RCTs) have tested semaglutide in pregnant women.
  
• Long-term effects on fetal development, birth outcomes, and childhood metabolic health are unknown.
  
• There is little data on whether early exposure during the preconception or first-trimester window poses specific risks.
  

This lack of evidence leaves providers and patients navigating uncertainty, often relying on animal data and expert consensus.

What to Discuss With Your Doctor

If you are taking semaglutide and planning to get pregnant—or already are—it’s essential to speak with your healthcare provider. Questions to ask may include:

• When should I stop semaglutide if I want to conceive?
  
• Are there safer alternatives during pregnancy?
  
• Do I need additional monitoring after stopping semaglutide?
  
• Will my weight or blood sugar be harder to control off the drug?
  
• What timeline is realistic for switching medications?
  

For women with diabetes, a transition plan to insulin or metformin should be developed. For those taking semaglutide for weight loss, options like nutritional counselling, behavioural support, and physical activity may be explored.

Alternatives to Semaglutide if You’re TTC

If you’re planning to conceive but require support for weight or metabolic health, these are safer options:

It’s important to create a personalized plan that balances metabolic health and pregnancy safety, especially if you’re dealing with obesity, PCOS, or prediabetes.

Summary

Semaglutide is not considered safe during pregnancy due to limited human data and concerning animal studies. It should be discontinued at least 2 months before conception, and is not recommended while trying to conceive. If pregnancy occurs during treatment, the medication should be stopped immediately, and follow-up care initiated.

Until better research is available, healthcare providers must guide patients individually, weighing the benefits of semaglutide against its unknown risks. Women planning pregnancy should consider safer, proven alternatives and have an open conversation with their doctors about timing, medication changes, and reproductive goals.